NCT06296979 Effectiveness of Noninvasive Phrenic Nerve Neuromodulation in Shoulder Pain and Hepatobiliary Visceral Comorbidity.
| NCT ID | NCT06296979 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Seville |
| Condition | Shoulder Pain |
| Study Type | INTERVENTIONAL |
| Enrollment | 34 participants |
| Start Date | 2024-03-20 |
| Primary Completion | 2026-12-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 34 participants in total. It began in 2024-03-20 with a primary completion date of 2026-12-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Pain, particularly shoulder pain, is a social and economic problem worldwide. Although visceral pathology is not yet taken into account in the diagnosis of these pains, it is likely that on numerous occasions the hepatobiliary visceral condition causes referred pain in the metameric area belonging to the shoulder due to the involvement of the phrenic nerve. Therefore, the aim of this project is to study the response of treatment by neuromodulation of the phrenic nerve for shoulder pain in patients with associated hepatobiliary pathologies, assessing the possible visceral involvement in the symptomatology.
Eligibility Criteria
Inclusion Criteria: * Over 18 years of age. * Subjects presenting right shoulder pain at the time of enrollment in the study. * Presentation of a hepatobiliary visceral disorder that may justify the visceral etiology of the pain. * That they agree to participate in the project by signing the informed consent form. Exclusion Criteria: * Patients with chronic pain due to other diseases such as malignant disease. * Patients with rheumatic diseases. * Cutaneous infection in the area of pain. * Disease of neurological, traumatic, oncologic, or infectious origin that rules out the visceral origin of the pain. * Uncooperative subject. * Severe psychiatric disease. * Loss of cognitive capacity. * Contraindication to electrotherapy.
Contact & Investigator
Ángel Oliva Pascual-Vaca, Dr
PRINCIPAL INVESTIGATOR
University of Seville
Frequently Asked Questions
Who can join the NCT06296979 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Shoulder Pain. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06296979 currently recruiting?
Yes, NCT06296979 is actively recruiting participants. Contact the research team at adolforosadoportillo@gmail.com for enrollment information.
Where is the NCT06296979 trial being conducted?
This trial is being conducted at Seville, Spain, Seville, Spain, Seville, Spain, Morón de la Frontera, Spain.
Who is sponsoring the NCT06296979 clinical trial?
NCT06296979 is sponsored by University of Seville. The principal investigator is Ángel Oliva Pascual-Vaca, Dr at University of Seville. The trial plans to enroll 34 participants.